A novel liquid biopsy based on ultra-deep next-generation sequencing (NGS) of plasma cell-free DNA (cfDNA) can detect oncogenic drivers and resistance mutations in non-small-cell lung cancer (NSCLC), even when tissue biopsy fails to do so, researchers say.
Reuters Health Information
